With hits and misses in first pivotal trials, J&J confidently maps a path to the FDA with its major depression med esketamine

J&J researchers rolled out data from the first two pivotal trials of their anti-depression drug esketamine today, blazing a trail that they say leads straight to an FDA filing in a matter of months with a groundbreaking approach to treating major depression.